NZ604801A - Synthesis and use of focal adhesion kinase inhibitors - Google Patents
Synthesis and use of focal adhesion kinase inhibitorsInfo
- Publication number
- NZ604801A NZ604801A NZ60480111A NZ60480111A NZ604801A NZ 604801 A NZ604801 A NZ 604801A NZ 60480111 A NZ60480111 A NZ 60480111A NZ 60480111 A NZ60480111 A NZ 60480111A NZ 604801 A NZ604801 A NZ 604801A
- Authority
- NZ
- New Zealand
- Prior art keywords
- focal adhesion
- adhesion kinase
- synthesis
- kinase inhibitors
- fak
- Prior art date
Links
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 title abstract 3
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 4
- 238000006243 chemical reaction Methods 0.000 abstract 3
- 239000003054 catalyst Substances 0.000 abstract 2
- 229910052763 palladium Inorganic materials 0.000 abstract 2
- 150000001448 anilines Chemical class 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 150000001502 aryl halides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35994210P | 2010-06-30 | 2010-06-30 | |
| PCT/US2011/042169 WO2012012139A1 (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ604801A true NZ604801A (en) | 2015-03-27 |
Family
ID=45497129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ60480111A NZ604801A (en) | 2010-06-30 | 2011-06-28 | Synthesis and use of focal adhesion kinase inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9505719B2 (https=) |
| EP (1) | EP2588476A4 (https=) |
| JP (1) | JP5923499B2 (https=) |
| CN (1) | CN103168037A (https=) |
| AU (1) | AU2011280031B2 (https=) |
| CA (1) | CA2803005A1 (https=) |
| MX (1) | MX343894B (https=) |
| NZ (1) | NZ604801A (https=) |
| WO (1) | WO2012012139A1 (https=) |
| ZA (1) | ZA201300012B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2675793B1 (en) | 2011-02-17 | 2018-08-08 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| JP5937112B2 (ja) | 2011-02-17 | 2016-06-22 | カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｒｃ Ｐｔｙ Ｌｉｍｉｔｅｄ | 選択的ｆａｋ阻害剤 |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4656182A (en) * | 1983-12-06 | 1987-04-07 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
| US20040006005A1 (en) | 2002-07-02 | 2004-01-08 | Sanjay Bhanot | Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0114814A (pt) | 2000-10-11 | 2005-01-25 | Cephalon Inc | Composições compreendendo composto de modafinila e seu uso |
| AR040456A1 (es) * | 2002-06-27 | 2005-04-06 | Bristol Myers Squibb Co | Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana |
| US20080119515A1 (en) | 2003-03-10 | 2008-05-22 | M Arshad Siddiqui | Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis |
| GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
| ES2533258T3 (es) | 2005-02-18 | 2015-04-08 | Janssen Sciences Ireland Uc | Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH |
| WO2007050574A1 (en) | 2005-10-25 | 2007-05-03 | Abbott Laboratories | Formulation comprising a drug of low water solubility and method of use thereof |
| EP2012753A2 (en) * | 2006-04-28 | 2009-01-14 | Schering Corporation | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same |
| CN101495095B (zh) * | 2006-04-28 | 2013-05-29 | 默沙东公司 | 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂 |
| EP2046292B1 (en) | 2006-07-21 | 2010-03-03 | Novartis AG | Formulations for benzimidazolyl pyridyl ethers |
| DK2134689T3 (da) * | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
| WO2009100176A2 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| MX2010014057A (es) * | 2008-06-17 | 2011-03-21 | Astrazeneca Ab | Compuestos de piridina. |
| CN102648197A (zh) | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | 促进细胞凋亡和抑制转移的方法 |
| WO2011133668A2 (en) | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2011
- 2011-06-28 MX MX2012014986A patent/MX343894B/es active IP Right Grant
- 2011-06-28 WO PCT/US2011/042169 patent/WO2012012139A1/en not_active Ceased
- 2011-06-28 CA CA2803005A patent/CA2803005A1/en not_active Abandoned
- 2011-06-28 AU AU2011280031A patent/AU2011280031B2/en not_active Ceased
- 2011-06-28 JP JP2013518575A patent/JP5923499B2/ja not_active Expired - Fee Related
- 2011-06-28 CN CN2011800421749A patent/CN103168037A/zh active Pending
- 2011-06-28 NZ NZ60480111A patent/NZ604801A/en not_active IP Right Cessation
- 2011-06-28 EP EP11810100.5A patent/EP2588476A4/en not_active Withdrawn
-
2013
- 2013-01-02 ZA ZA2013/00012A patent/ZA201300012B/en unknown
- 2013-08-07 US US13/961,517 patent/US9505719B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20140235635A1 (en) | 2014-08-21 |
| JP5923499B2 (ja) | 2016-05-24 |
| CA2803005A1 (en) | 2012-01-26 |
| ZA201300012B (en) | 2013-09-25 |
| MX343894B (es) | 2016-11-28 |
| AU2011280031B2 (en) | 2015-09-10 |
| AU2011280031A1 (en) | 2013-01-10 |
| MX2012014986A (es) | 2013-07-03 |
| US9505719B2 (en) | 2016-11-29 |
| EP2588476A4 (en) | 2014-07-23 |
| EP2588476A1 (en) | 2013-05-08 |
| JP2013529687A (ja) | 2013-07-22 |
| CN103168037A (zh) | 2013-06-19 |
| WO2012012139A1 (en) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX348623B (es) | Proceso y sistema de reaccion para la preparacion de metanol. | |
| PH12014502775A1 (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| MY166026A (en) | Tetrahydro-pyrido-pyrimidine derivatives | |
| TN2011000404A1 (en) | Fused pyrimidines | |
| WO2012087628A3 (en) | Production of polycrystalline silicon by the thermal decomposition of dichlorosilane in a fluidized bed reactor | |
| EG27128A (en) | Process for the production of light olefins from synthesis gas | |
| MX350643B (es) | Procedimiento para la produccion de acetato de vinilo. | |
| MX2012008932A (es) | Proceso para la integracion de calor para la produccion de etanol y proceso de purificacion. | |
| EP4357020A3 (en) | Asymmetric phase transfer catalysis | |
| MX350003B (es) | Procedimiento para la fabricación de derivados de dibenzoilmetano. | |
| MX2012007868A (es) | Metodo para preparar sales de acido tetrazol-mentasulfonico, y un nuevo compuesto utilizado en las mismas. | |
| MY157423A (en) | Production method of intermediate compound for synthesizing medicament | |
| EP2382434A1 (de) | Verfahren zur thermischen behandlung von zementrohmehl in einem reaktionsraum | |
| NZ604801A (en) | Synthesis and use of focal adhesion kinase inhibitors | |
| MX2012006524A (es) | Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol. | |
| AU2012264468A1 (en) | Catalytic process for the conversion of a synthesis gas to hydrocarbons | |
| MX2013000294A (es) | Intermedios y procedimiento de preparación de un inhibidor específico de la trombina. | |
| GB201104203D0 (en) | Chemical process | |
| GB2497841A (en) | Subsea hydrocarbon production system | |
| GB2489362B (en) | Process for the conversion of synthesis gas | |
| MX356357B (es) | Metodos para producir molindona y sus sales. | |
| TR201903717T4 (tr) | Sentez gazından etanol üretiminde kontamine edici organizmalardan kaynaklanan istenmeyen yan ürünlerin oluşumunun kontrol edilmesine yönelik yöntem. | |
| SA112330994B1 (ar) | عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً | |
| WO2012050623A3 (en) | Novel phenoxyisobutyric acid compounds and methods for synthesis | |
| WO2011104634A3 (pt) | Produção de propilenoglicol a partir de glicerina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S23 | Proceedings under section 23: mention of inventor as such in patent |
Free format text: INVENTOR CONNIE, SUN ADDED Effective date: 20130221 Free format text: INVENTOR LI, HUI-YIN REMOVED Effective date: 20130221 |
|
| ASS | Change of ownership |
Owner name: VERASTEM, INC, US Effective date: 20140313 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20150818 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180918 |
|
| LAPS | Patent lapsed |